Narjust Florez
MD
Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Dec 23, 2025
Episode
340
Soundcloud
Share
This episode of Lung Cancer Considered breaks down the FDA approval of subcutaneous amivantamab. Join host Dr. Narjust Florez and guests, Dr. Natasha Leighl and Dr. Federico Cappuzzo, as they explore the science and convenience factor, as well as what this shift means for patients, clinicians, and oncology practice.
Guest
Federico Cappuzzo
MD
Director of Medical Oncology
National Cancer Institute Regina Elena in Rome
AUSL della Romagna, Ravenna, Italy
Natasha Leighl
MD, FASCO
Thoracic Medical Oncology Group Lead
Princess Margaret Cancer Centre
